In this study, our results reported that LGR6 was differentially upregulated in different histologic types of ovarian cancer, particularly in high-grade serous adenocarcinoma, and high expression of LGR6 positively correlated with histologic types, FIGO stages, poor chemotherapeutic response, and poor progression in ovarian cancer patients. This evidence concerns the gene LGR6 and ovarian carcinoma.